Skip to main content
OXYGENTA PHARMACEUTICAL LIMITED logo

OXYGENTA PHARMACEUTICAL LIMITED — Investor Relations & Filings

Ticker · 524636 ISIN · INE102E01018 LEI · 984500FB9E6H1072B907 BSE.NS Manufacturing
Open in API
Filings indexed 5 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country IN India
Listing BSE.NS 524636

About OXYGENTA PHARMACEUTICAL LIMITED

https://www.oxygentapharma.com

Oxygenta Pharmaceutical Limited focuses on the development, manufacturing, and commercialization of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The company maintains a diverse product portfolio catering to various therapeutic segments, including anti-fungals, anti-infectives, and other specialty chemical applications. Utilizing modern manufacturing infrastructure, the organization adheres to rigorous quality control protocols to ensure compliance with global standards. Its core competencies include complex chemical synthesis, process optimization, and large-scale production capabilities. Oxygenta provides integrated solutions ranging from research and development to contract manufacturing services, supporting the requirements of global healthcare partners through technical expertise and scalable manufacturing processes.

Recent filings

Filing Released Lang Actions
Annual Secretarial Compliance Report for the year ended 31.03.2026 pursuant to Regulation 24A of SEBI (LODR) Regulations, 2018.
Regulatory Filings Classification · 85% confidence The document is an Annual Secretarial Compliance Report submitted under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is a detailed compliance report provided to the stock exchange, containing tables of regulatory adherence, examination scope, and conclusions by a Practicing Company Secretary. It is not announcing the publication of another report (it contains the full report), nor is it an annual financial report, earnings release, management discussion, or any other narrowly defined category. Thus, it falls under general regulatory filings.
2026-05-26 English
Change in Management by way of appointment of Additional Directors and Internal Auditor.
Interim / Quarterly Report Classification · 87% confidence The document is an official Outcome of Board Meeting filed to the stock exchange under SEBI LODR. It contains actual audited standalone financial results for the quarter and year ended 31 March 2026 (complete tables and notes), together with auditor declarations and board approvals. It is not merely an announcement that a report is available (so not RPA), nor a full annual report (10-K), nor only an audit opinion (AR). It clearly includes comprehensive quarter‐end financial statements, fitting the definition of an Interim/Quarterly Report (IR). FY 2026
2026-05-23 English
Audited Financial Results for the Quarter and Year ended 31.03.2026.
Regulatory Filings Classification · 75% confidence The document is a regulatory filing under SEBI Listing Obligations used to inform the stock exchange of the board meeting outcome, including approval of audited results, auditor’s declaration, director appointments, internal auditor appointment, and notice of the AGM. It is not a standalone full annual report (10-K), nor solely a quarterly/interim report (IR) or earnings release (ER), but a multi-item compliance announcement under Indian exchange rules. This fits the general Regulatory Filings (RNS) category.
2026-05-23 English
Outcome of the Board meeting held on 23rd May, 2026.
Interim / Quarterly Report Classification · 85% confidence The document is a formal SEBI LODR filing (“Outcome of Board Meeting”) dated 23.05.2026, announcing and attaching the audited financial results for the quarter and year ended 31.03.2026, along with the auditors’ report. It contains a full “Statement of Audited Standalone Financial Results” table with line-by-line figures, notes, and supporting declarations. It is not merely an earnings teaser or notice of publication; it includes substantive financial statements for the quarter (an interim period) and year-to-date numbers, satisfying the criteria for an Interim/Quarterly Report rather than an Annual Report or simple earnings release. Therefore, it is classified as an Interim / Quarterly Report. FY 2026
2026-05-23 English
Oxygenta Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2026 ,inter alia, to consider and approve 1. Audited Financial ....
Regulatory Filings Classification · 82% confidence The document is an intimation letter to the stock exchange under SEBI LODR, notifying the date of a forthcoming Board Meeting to consider audited financial results and the audit report. It does not contain the results themselves or any substantive financial data, nor is it announcing any change in board composition or executive management. It is not a proxy, dividend, or AGM materials. Therefore, it falls into the general regulatory announcement/filer compliance category as a Regulatory Filing.
2026-05-19 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.